ClinicalTrials.gov
public full text
Public Domain
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
Evaluation of the clinical profile (lipid efficacy, safety and PK) across a number of doses of CIVI 007, a PCSK9 inhibitor. Patients to be evaluated will be on a stable background of statin therapy with or without ezetimibe.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Evidence review for statins: efficacy and adverse effects: Cardiovascular disease: risk assessment and reduction, including lipid modification: Evidence review C#2214
- PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis#850065
- A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins#846835
- Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus#148650
- Intensive Lipid Lowering Treatment in Non-ST-elevation Acute Coronary Syndrome (NSTE-ACS) Patients#835283
Record · ID 1044667
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive